MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT
Authors
Keywords
Glioblastoma, Temozolomide resistance, miR-198, MGMT
Journal
JOURNAL OF NEURO-ONCOLOGY
Volume 133, Issue 1, Pages 59-68
Publisher
Springer Nature
Online
2017-04-19
DOI
10.1007/s11060-017-2425-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Post-transcriptional regulation of O6-methylguanine-DNA methyltransferase MGMT in glioblastomas
- (2017) Valya Ramakrishnan et al. Cancer Biomarkers
- BACH1 Promotes Temozolomide Resistance in Glioblastoma through Antagonizing the Function of p53
- (2016) Er Nie et al. Scientific Reports
- β-Catenin is involved in Bex2 down-regulation induced glioma cell invasion/migration inhibition
- (2015) Er Nie et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- miR-198 Represses the Proliferation of HaCaT Cells by Targeting Cyclin D2
- (2015) Jian Wang et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- A genome-wide miRNA screen revealed miR-603 as a MGMT-regulating miRNA in glioblastomas
- (2015) Deepa Kushwaha et al. Oncotarget
- Regulatory Roles of miRNA in the Human Neural Stem Cell Transformation to Glioma Stem Cells
- (2014) Shuang Liu et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- In human glioblastomas transcript elongation by alternative polyadenylation and miRNA targeting is a potent mechanism of MGMT silencing
- (2013) Simone Kreth et al. ACTA NEUROPATHOLOGICA
- ‘See-saw’ expression of microRNA-198 and FSTL1 from a single transcript in wound healing
- (2013) Gopinath M. Sundaram et al. NATURE
- Adult-specific functions of animal microRNAs
- (2013) Kailiang Sun et al. NATURE REVIEWS GENETICS
- miR-221/222 Target the DNA Methyltransferase MGMT in Glioma Cells
- (2013) Cristina Quintavalle et al. PLoS One
- mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy
- (2013) M. Weiler et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- MiR-21 Modulates hTERT Through a STAT3-Dependent Manner on Glioblastoma Cell Growth
- (2012) Ying-Yi Wang et al. CNS Neuroscience & Therapeutics
- A Systematic Review of MicroRNA in Glioblastoma Multiforme: Micro-modulators in the Mesenchymal Mode of Migration and Invasion
- (2012) Heidi G. Møller et al. MOLECULAR NEUROBIOLOGY
- miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression
- (2012) W. Zhang et al. NEURO-ONCOLOGY
- miR-198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway
- (2011) Sheng Tan et al. FEBS LETTERS
- miR-195, miR-455-3p and miR-10a∗ are implicated in acquired temozolomide resistance in glioblastoma multiforme cells
- (2010) Kenta Ujifuku et al. CANCER LETTERS
- MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients
- (2010) O. Slaby et al. NEOPLASMA
- Temozolomide in malignant gliomas: current use and future targets
- (2009) J. Lee Villano et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Glioma Stem Cell Lines Expanded in Adherent Culture Have Tumor-Specific Phenotypes and Are Suitable for Chemical and Genetic Screens
- (2009) Steven M. Pollard et al. Cell Stem Cell
- Concordant Regulation of Translation and mRNA Abundance for Hundreds of Targets of a Human microRNA
- (2009) David G. Hendrickson et al. PLOS BIOLOGY
- DNA repair and cancer stem-like cells – Potential partners in glioma drug resistance?
- (2008) Tor-Christian Aase Johannessen et al. CANCER TREATMENT REVIEWS
- Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma
- (2008) J. N. Sarkaria et al. CLINICAL CANCER RESEARCH
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started